Harry Levine

Harry Levine

Auto-generated profile, based on publicly available information

Harry Levine

Department of Molecular and Cellular Biochemistry, Chandler School of Medicine and the Center on Aging, University of Kentucky, Lexington, KY, USA. hlevine@.uky.edu

Research Focus & Metrics

Academic Career Length

87Years (1940-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2010 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
MMM Paul Murphy
M Paul Murphy
HLHarry LeVine
Harry LeVine
Alzheimer's disease (AD) pathogenesis is widely believed to be driven by the production and deposition of the amyloid-β peptide (Aβ). For many years, investigators have been puzzled by the weak to nonexistent correlation between the amount of neuriti

1 December 2004 in Analytical Biochemistry
Verified
Journal Article
Closed access
HIHarry LeVine III
Harry LeVine III

1 March 2005 in Amyloid
Verified
Journal Article
Closed access
ILIii Harry Levine
Iii Harry Levine
Although the structures of Thioflavin T and another benzothiazole, BTA-1, are similar, they bind to Aß non-competitively, probably to different sites on the Aß (1–40) fibrils. The amyloid fibril-induced fluorescence of ThT that corresponds to a fraction of total ThT binding is not displaced by high concentrations of (S)-naproxen or (R)-ibuprofen, which are reported to potently block high affinity binding of the radiolabeled malononitrile FDDNP and derivatives. The binding of the benzothiazole ligands is significantly substoichiometric with respect to Aß (1–40) monomer peptide, unlike Congo Red, which binds to Aß (1–40) fibrils on a 1:1 basis with monomer peptide. These results indicate that there are multiple domains for ligand binding to amyloid fibrils and suggest that it may be possible to design ligands that bind selectively to particular forms of fibrils that are connected with the pathogenesis of Alzheimer's disease and potentially other protein misfolding diseases.

16 May 2006 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
LWLary Walker
Lary Walker
HLHarry LeVine
Harry LeVine
MJMathias Jucker
Mathias Jucker

1 September 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LWLary C. Walker
Lary C. Walker
HLHarry LeVine
Harry LeVine
With advancing age, the brain becomes increasingly susceptible to neurodegenerative diseases, most of which are characterized by the misfolding and errant aggregation of certain proteins. The induction of aggregation involves a crystallization-like seeding mechanism by which a specific protein is structurally corrupted by its misfolded conformer. The latest research indicates that, once formed, proteopathic seeds can spread from one locale to another via cellular uptake, transport, and release. Impeding this process could represent a unified therapeutic strategy for slowing the progression of a wide range of currently intractable disorders.

1 January 2007 in Amyloid
Verified
Journal Article
Closed access
HLHarry Levine
Harry Levine
The Aβ peptide assembles into a variety of distinct types of structures in vitro and in the brain which have different biological consequences. Differential effects of inhibitory small molecules suggest that a sequential monomer – oligomer – fibril mechanism is overly simplistic and that soluble toxic oligomers and fibrils can be formed in common or separate pathways depending on the local environment. As a result, the effects of inhibitors are often assay-dependent because multiple pathways are operating. This review discusses strategies for teasing apart the intricate protein–protein interactions that result in Aβ assembly.